Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.
Location: United States, California, San Francisco
Employees: 1-10
Total raised: $92M
Founded date: 2016
Investors 2
| Date | Name | Website |
| 15.07.2021 | Dolby Fami... | dolbyventu... |
| 27.11.2023 | MRL Ventur... | mrlv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.05.2025 | Series A | $39M | - |
| 28.04.2023 | Series A | $36M | Dolby Fami... |
| 10.05.2021 | Seed | $17M | - |
Mentions in press and media 14
| Date | Title | Description |
| 17.05.2025 | Therini Bio Secures $39 Million to Combat Neurodegenerative Diseases | In the ever-evolving landscape of biotechnology, Therini Bio, Inc. has made headlines by securing an additional $39 million in Series A financing. This funding is a beacon of hope for those grappling with neurodegenerative diseases. Based i... |
| 17.05.2025 | Therini Bio: $39 Million Series A Secured For Advancing Clinical Development Of Neurodegenerative Disease Immunotherapies | Therini Bio – a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction – announced that it raised $39 million in a Series A extension financing. This extensio... |
| 15.05.2025 | Therini Bio Raises Additional $39M in Series A Financing | Therini Bio, Inc., a Sacramento, CA-based clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction raised $39m in Series A extension financing. The extension fi... |
| 14.05.2025 | Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline | Sacramento, May 14, 2025 (GLOBE NEWSWIRE) - Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that it raised $39 mil... |
| 29.04.2025 | Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases | Sacramento, April 29, 2025 (GLOBE NEWSWIRE) – Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced positive results fro... |
| 10.06.2024 | ALZHEIMER'S DRUG DISCOVERY FOUNDATION'S (ADDF) STATEMENT ON FDA ADVISORY COMMITTEE'S ENDORSEMENT OF DONANEMAB | While the endorsement of a second anti-amyloid is emblematic of a new era, a combination therapy and precision medicine approach will be needed to guide the next generation of treatments. NEW YORK, June 10, 2024 /PRNewswire/ -- Today, the F... |
| 08.05.2024 | Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases | Sacramento, May 8, 2024 (GLOBE NEWSWIRE) — Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction, today announced positive preclinical d... |
| 28.04.2023 | Startup Therini Bio Lands $36M to Take Blood Protein R&D to Alzheimer’s & More | The blood protein fibrin plays a key role in stopping bleeding, but in certain circumstance it can also contribute to disease. Therein lies the challenge for developing a fibrin-targeting drug. Scientists need to figure out how to stop the ... |
| 27.04.2023 | Therini Bio Raises $36M Series A Financing | Therini Bio, a South San Francisco, CA-based biotech company that provides fibrin-targeted therapies, raised $36M in Series A funding. The round, which brought the total amount to $62M, was co-led by Dementia Discovery Fund, MRL Ventures Fu... |
| 27.04.2023 | Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases | Funding from top-tier syndicate will be used to advance potential first-in-class investigational antibody THN391 into clinical trials. |
Show more